<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Thiopental</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00599</strong>&#160; (APRD00660)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00599/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00599/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00599.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00599.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00599.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00599.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00599.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00599">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Bitaryl</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Omexolon</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Sodium Pentothal</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Thiomebumalum</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Thiopentone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tiopentale</td><td>Italian</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Trapanal</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Anestho</td><td>Incepta</td></tr><tr><td>Bensulf</td><td>Fada </td></tr><tr><td>Bitol Sodium</td><td>Brookes</td></tr><tr><td>Ekipental</td><td>T&#252;m Ekip</td></tr><tr><td>Farmotal</td><td>Marvecs Pharma Services</td></tr><tr><td>Intraval Sodium</td><td>Abbott</td></tr><tr><td>Pental Sodyum</td><td>I.E. Ulagay</td></tr><tr><td>Pentazol</td><td>Swiss Parenterals</td></tr><tr><td>Penthal</td><td>Oboi</td></tr><tr><td>Penthotal Sodium</td><td>Abbott</td></tr><tr><td>Pentotan</td><td>Choong Wae</td></tr><tr><td>Pentotex</td><td>Rotexmedica</td></tr><tr><td>Pentothal</td><td>Hospira</td></tr><tr><td>Ravonal</td><td>Ravonal</td></tr><tr><td>Thiopen</td><td>ACI</td></tr><tr><td>Tiopental</td><td>Richmond</td></tr><tr><td>Trapanal</td><td>Nycomed</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Thiotal 5g</td><td>Thiopental Sodium + Water</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypnotics-and-sedatives">Hypnotics and Sedatives</a></li>
<li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/anesthetics-intravenous">Anesthetics, Intravenous</a></li>
<li><a href="/mesh/gaba-modulators">GABA Modulators</a></li></ul></td></tr><tr><th>CAS number</th><td>76-75-5</td></tr><tr><th>Weight</th><td>Average: 242.338<br>Monoisotopic: 242.10889852</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>IUJDSEJGGMCXSG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-ethyl-5-(pentan-2-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCC(C)C1(CC)C(=O)NC(=S)NC1=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00599.gif?1265922774">show</a>(9.6 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrimidines and Pyrimidine Derivatives</td></tr><tr><th>Direct parent</th><td>Thiobarbituric Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Diazinanes; Secondary Carboxylic Acid Amides; Organic Thiocarbonic Acid Derivatives; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>1,3-diazinane; secondary carboxylic acid amide; carboxamide group; thiocarbonic acid derivative; carboxylic acid derivative; polyamine; carboxylic acid; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the thiobarbituric acid derivatives. These are organic compounds containing a 2-thioxodihydropyrimidine-4,6(1H,5H)-dione skeleton.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use as the sole anesthetic agent for brief (15 minute) procedures, for induction of anesthesia prior to administration of other anesthetic agents, to supplement regional anesthesia, to provide hypnosis during balanced anesthesia with other agents for analgesia or muscle relaxation, for the control of convulsive states during or following inhalation anesthesia or local anesthesia, in neurosurgical patients with increased intracranial pressure, and for narcoanalysis and narcosynthesis in psychiatric disorders.</td></tr><tr><th>Pharmacodynamics</th><td>Thiopental, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Thiopental is an ultrashort-acting depressant of the central nervous system which induces hypnosis and anesthesia, but not analgesia. It produces hypnosis within 30 to 40 seconds of intravenous injection. Recovery after a small dose is rapid, with some somnolence and retrograde amnesia. Repeated intravenous doses lead to prolonged anesthesia because fatty tissues act as a reservoir; they accumulate Pentothal in concentrations 6 to 12 times greater than the plasma concentration, and then release the drug slowly to cause prolonged anesthesia</td></tr><tr><th>Mechanism of action</th><td>Thiopental binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Approximately 80% of the drug in the blood is bound to plasma protein.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic. Biotransformation products of thiopental are pharmacologically inactive and mostly excreted in the urine.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3-8 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Overdosage may occur from too rapid or repeated injections. Too rapid injection may be followed by an alarming fall in blood pressure even to shock levels. Apnea, occasional laryngospasm, coughing and other respiratory difficulties with excessive or too rapid injections may occur. Lethal blood levels may be as low as 1 mg/100 mL for short-acting barbiturates; less if other depressant drugs or alcohol are also present.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.5106</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9505</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5463</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5623</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5373</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8381</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9031</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8052</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.858</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6688</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8297</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5588</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.914</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5927</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8813</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8482</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6907
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8992
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9917
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7671 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9827
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6314
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abbott laboratories hosp products div</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Thiopental may increase the metabolism of the Vitamin K antagonist, Acenocoumarol. Acenocoumarol dose adjustment may be required.</td></tr><tr><td><a href="/drugs/DB00381">Amlodipine</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Amlodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Amlodipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Chloramphenicol may increase the serum concentration of Thiopental by decreasing Thiopental metabolism. Thiopental may decrease the serum concentration of Chloramphenicol by increasing Chloramphenicol metabolism. Monitor for changes in therapeutic effects of both agents if concomitant therapy is initiated, discontinued or doses are adjusted. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Thiopental may increase the metabolism and clearance of Cyclosporine. Monitor for changes in the therapeutic/adverse effects of Cyclosporine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00304">Desogestrel</a></td><td>Thiopental may decrease the effect of Desogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Diltiazem, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Diltiazem if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Thiopental may increase the metabolism and clearance of Disopyramide. Monitor for changes in therapeutic/adverse effects of Disopyramide if Thiopental is inititaed, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Thiopental may decrease the serum levels of Doxycycline. A reduction in antimicrobial effects may occur. An alternative antibiotic may be considered. </td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Thiopental may decrease the effect of Drospirenone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Thiopental may decrease the effect of Ethinyl estradiol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00823">Ethynodiol</a></td><td>Thiopental may decrease the effect of Ethynodiol diacetate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00294">Etonogestrel</a></td><td>Thiopental may decrease the effect of Etonogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Felodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Felodipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00270">Isradipine</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Isradipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Isradipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Thiopental may increase the metabolism and clearance of Lamotrigine. Monitor for decreased therapeutic effect of Lamotrigine if Thiopental is initiated.</td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Thiopental may decrease the effect of Levonorgestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>Thiopental may decrease the effect of Medroxyprogesterone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>Thiopental may decrease the effect of Mestranol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Thiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur. </td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nicardipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nicardipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01115">Nifedipine</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nifedipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nifedipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00393">Nimodipine</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nimodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nimodipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00401">Nisoldipine</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nisoldipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nisoldipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01054">Nitrendipine</a></td><td>The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nitrendipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nitrendipine if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>Thiopental may decrease the effect of Norethindrone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00957">Norgestimate</a></td><td>Thiopental may decrease the effect of Norgestimate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Thiopental may increase the metabolism and clearance of Propafenone. Monitor for decreased therapeutic effect of Propafenone if Thiopental is initiated.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Thiopental may increase the metabolism and clearance of Quinidine. Monitor for decreased therapeutic effect of Quinidine if Thiopental is initiated.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The barbiturate, Thiopental, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Thiopental is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Thiopental, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Thiopental, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Thiopental is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>